This post was originally published on this site Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists identify those who may benefit the most from Opdivo (nivolumab) as a first line of treatment before starting therapy, according to a Phase 3 clinical trial. The results…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Aquablation Safe, Potentially More Efficient than TURP, Phase 3 Trial Suggests
This post was originally published on this site Aquablation is a safe and more efficient procedure to treat men with symptoms of benign prostatic hyperplasia (BPH) than is TURP, according to early results of the Phase 3 WATER trial (NCT02505919). Preliminary trial safety and efficacy findings were presented at the recent American Urological Association (AUA) Annual Meeting in…
Prostate Cancer UK Grants $355K to University of Birmingham for Development of New Test
This post was originally published on this site Prostate Cancer UK has awarded more than $355,000 (£275,000) to University of Birmingham researchers to develop a diagnostic tool that can measure the aggressiveness of a patient’s prostate cancer. The new technology will help physicians identify the best course of treatment for each patient. The grant is part…
Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows
This post was originally published on this site Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, results of a Phase 3 trial show. The benefits were seen across multiple patient subgroups, regardless of initial…
Grants Will Fuel UK Researchers’ Drive Toward Prostate Cancer-Killing Virus
This post was originally published on this site Scientists from the Queen Mary University of London have received grants worth more than £2.5 million ($3.2 million), awarded by Prostate Cancer UK to advance prostate cancer research. The funds, which are part of the charity’s Research Innovation Awards scheme, aim to foster innovative and ambitious research projects across the…
University of Minnesota Team Receives $1M to Develop CAR-NK Therapy
This post was originally published on this site The Prostate Cancer Foundation (PCF) has granted a $1 million Challenge Award to researchers from the Masonic Cancer Center at the University of Minnesota to support their investigations into new therapies for prostate cancer. With this award, the PCF hopes to accelerate the development of strategies to improve…
HPN424 Shows Promising Safety, Immune Activation in Metastatic CRPC
This post was originally published on this site Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) patients. The multicenter, international, open-label study (NCT03577028) is assessing the safety, tolerability and overall stability and distribution of…
Breast Cancer Treatments Could Be Used for Rare Ovarian Cancer, Study Suggests
This post was originally published on this site Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a study suggests. The study, “CDK4/6 inhibitors target SMARCA4-determined cyclin D1…
Phase 1 Trial Approved to Test PRGN-3005 UltraCAR-T for Advanced Platinum-resistant Ovarian Cancer
This post was originally published on this site Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application. The open-label, dose-escalation study will assess the treatment’s safety and maximum tolerated dose.…
1st Patient Dosed in Phase 1/2 Trial of COTI-2 Plus Chemo for Gynecological and Other Solid Cancers
This post was originally published on this site A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga Pharmaceuticals, the potential treatment’s developer, announced. The clinical trial (NCT02433626) was first designed to evaluate the safety and…
Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds
This post was originally published on this site A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a Phase 1/2 trial shows. The findings suggest that weekly chemotherapy might be more suitable for these patients…
Losartan May Improve Ovarian Cancer Treatment, Study Finds
This post was originally published on this site Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with advanced ovarian cancer receiving losartan or other similar angiotensin signaling inhibitors lived a median 30 months longer on standard…